

## TRIAL SCHEDULE 2021-2022

	BCR-ABL1 and AML Translocation Identification (Accredited)	BCR-ABL1 Major Quantification (Accredited)	Post-Stem Cell Transplant Chimerism Monitoring (Accredited)	IgH/TCR Clonality Status (Accredited)	JAK2 p.Val617Phe (V617F) Mutation Status (Accredited)	FLT3 Mutation Status (Accredited)	NPM1 Mutation Status (Accredited)	BRAF p.Val600Glu (V600E) Mutation Status for Hairy Cell Leukaemia (Accredited)	KIT p.Asp816Val (D816V) Mutation Status for Mast Cell Disease (Accredited)	Paediatric Acute Leukaemia Translocations (Accredited)	BCR-ABL1 Kinase Domain Variant (Mutation) Status (Accredited)	BCR-ABL1 Minor Quantification (Pilot - Not Accredited)	Acute Myeloid Leukaemia and Myelodysplastic Syndrome Gene Panels (Pilot - Not Accredited)	Chronic Lymphocytic Leukaemia Gene Panels (Pilot - Not Accredited)	Myeloproliferative Neoplasms Gene Panels (Pilot - Not Accredited)	Lymphoplasmacytic Lymphoma / Waldenström Macroglobulinaemia (Pilot - Not Accredited)
Planned trial issues per financial year	3	3	5	3	3	3	3	3	3	3	3	2	2	1	1	2
APRIL 2021	X			X				X								
MAY 2021		X	X						X							X
JUNE 2021					X					X	X			X		
JULY 2021			X			X	X	X								
AUGUST 2021	X			X									X			
SEPTEMBER 2021		X							X			X			X	
OCTOBER 2021			X		X					X	X					
NOVEMBER 2021						X	X									X
DECEMBER 2021	X			X				X								
JANUARY 2022		X	X						X			X				
FEBRUARY 2022					X					X	X		X			
MARCH 2022			X			X	X									

Please note that this is a guide only. UK NEQAS for Leucocyte Immunophenotyping reserves the right to cancel or vary the number of shipments. Please note that your participation entitles you to the service and not the number of shipments.